Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2020 Jun 16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Urologica e Nefrologica 2020 Jun 16

DOI: 10.23736/S0393-2249.20.03739-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

PSMA PET/CT and staging high risk prostate cancer: a non-systematic review of high clinical impact literature

Joshua J. MORIGI 1 , Jack ANDERSON 1, Cosimo DE NUNZIO 2, Stefano FANTI 3

1 PET/CT Unit, Royal Darwin Hospital, Darwin, Australia; 2 Ospedale Sant Andrea, Sapienza University of Rome, Rome, Italy; 3 Metropolitan Nuclear Medicine Service, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy


PDF


INTRODUCTION: Prostate specific membrane antigen (PSMA) positron emission tomography (PET) with computed tomography (CT) is a promising molecular imaging technique for prostate cancer (PCa). Although not yet included in international guidelines, PSMA PET/CT is commonly used in clinical practice to stage patients with newly diagnosed PCa. This review focuses on the most up-to-date literature on staging high risk prostate cancer with PSMA PET/CT.
METHODS: An online based literature research encompassing original studies, reviews and meta-analysis was performed in the month of November of 2019. The most relevant and impactful research was then extracted based on the expertise of the authors, with the specific focus of highlighting the clinical impact and appropriateness of PSMA PET/CT in staging PCa.
RESULTS: The use of PSMA PET/CT is appropriate in all high-risk patients with newly diagnosed PCa as it will often have a significant clinical impact. Although preliminary findings are promising, there is still a scarcity of data regarding the performance of PSMA PET/CT vs other modalities in defining disease within the prostate gland. There is good evidence suggesting that PSMA PET/CT may be superior to every other imaging modality in assessing loco-regional and distant metastatic disease.
CONCLUSIONS: PSMA PET/CT has the potential to become a gold standard in staging high risk prostate cancer, providing clinicians with accurate information on the extent of disease within the prostate and the presence of loco-regional and distant metastatic disease within a single scan.


KEY WORDS: Prostate cancer; Molecular imaging; PSMA PET/CT

top of page